119 related articles for article (PubMed ID: 12071417)
1. Self-designing two-stage trials to minimize expected costs.
Thach CT; Fisher LD
Biometrics; 2002 Jun; 58(2):432-8. PubMed ID: 12071417
[TBL] [Abstract][Full Text] [Related]
2. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
3. The choice of sample size: a mixed Bayesian / frequentist approach.
Pezeshk H; Nematollahi N; Maroufy V; Gittins J
Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
[TBL] [Abstract][Full Text] [Related]
4. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
5. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
6. Statistical inference for self-designing clinical trials with a one-sided hypothesis.
Shen Y; Fisher L
Biometrics; 1999 Mar; 55(1):190-7. PubMed ID: 11318154
[TBL] [Abstract][Full Text] [Related]
7. A decision theoretic approach to sample size determination in clinical trials.
Gittins JC; Pezeshk H
J Biopharm Stat; 2002 Nov; 12(4):535-51. PubMed ID: 12477073
[TBL] [Abstract][Full Text] [Related]
8. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
Kikuchi T; Gittins J
Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
[TBL] [Abstract][Full Text] [Related]
9. A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials.
Cressie N; Biele J
Biometrics; 1994 Sep; 50(3):700-11. PubMed ID: 7981396
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian decision approach for sample size determination in phase II trials.
Leung DH; Wang YG
Biometrics; 2001 Mar; 57(1):309-12. PubMed ID: 11252615
[TBL] [Abstract][Full Text] [Related]
11. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
Willan A; Kowgier M
Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
[TBL] [Abstract][Full Text] [Related]
12. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
Cheng Y; Shen Y
Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
[TBL] [Abstract][Full Text] [Related]
13. Optimal choice of the number of treatments to be included in a clinical trial.
Stallard N; Posch M; Friede T; Koenig F; Brannath W
Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
[TBL] [Abstract][Full Text] [Related]
14. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
15. Bayesian techniques for sample size determination in clinical trials: a short review.
Pezeshk H
Stat Methods Med Res; 2003 Dec; 12(6):489-504. PubMed ID: 14653352
[TBL] [Abstract][Full Text] [Related]
16. A unified method for monitoring and analysing controlled trials.
Grossman J; Parmar MK; Spiegelhalter DJ; Freedman LS
Stat Med; 1994 Sep; 13(18):1815-26. PubMed ID: 7997715
[TBL] [Abstract][Full Text] [Related]
17. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
18. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
Ciarleglio MM; Arendt CD
Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis when the WTA is greater than the WTP.
Willan AR; O'Brien BJ; Leyva RA
Stat Med; 2001 Nov; 20(21):3251-9. PubMed ID: 11746316
[TBL] [Abstract][Full Text] [Related]
20. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
